Moderna (MRNA) has sold off over the past few weeks after running up on positive news about its personalized vaccine candidate for melanoma and its experimental RSV vaccine. This is likely due in part to profit-taking and in part to Pfizer (PFE) forecasting a larger-than-expected decline in sales of its COVID-19 vaccine and treatment for…